Maze Therapeutics, Inc.
MAZE
$25.56
-$0.87-3.29%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.27% | 34.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.32% | 15.45% | |||
| Operating Income | 30.23% | -15.45% | |||
| Income Before Tax | 29.97% | -14.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 29.97% | -14.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 29.97% | -14.89% | |||
| EBIT | 30.23% | -15.45% | |||
| EBITDA | 30.49% | -15.95% | |||
| EPS Basic | 30.61% | 1.49% | |||
| Normalized Basic EPS | 30.62% | 1.51% | |||
| EPS Diluted | 30.61% | 1.91% | |||
| Normalized Diluted EPS | 30.62% | 1.51% | |||
| Average Basic Shares Outstanding | 0.94% | 16.64% | |||
| Average Diluted Shares Outstanding | 0.94% | 16.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||